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RESEARCH ARTICLE Open Access
Long-term safety of secukinumab in
patients with moderate-to-severe plaque
psoriasis, psoriatic arthritis, and ankylosing
spondylitis: integrated pooled clinical trial
and post-marketing surveillance data
A. Deodhar1*, P. J. Mease2, I. B. McInnes3, X. Baraliakos4, K. Reich5,6, A. Blauvelt7, C. Leonardi8, B. Porter9,
A. Das Gupta10, A. Widmer11, L. Pricop9 and T. Fox11
Abstract
Background: Secukinumab, a fully human immunoglobulin G1-kappa monoclonal antibody that directly inhibits
interleukin (IL)-17A, has been shown to have robust efficacy in the treatment of moderate-to-severe psoriasis (PsO),
psoriatic arthritis (PsA), and ankylosing spondylitis (AS) demonstrating a rapid onset of action and sustained long-
term clinical responses with a consistently favorable safety profile in multiple Phase 2 and 3 trials. Here, we
report longer-term pooled safety and tolerability data for secukinumab across three indications (up to 5 years of
treatment in PsO and PsA; up to 4 years in AS).
Methods: The integrated clinical trial safety dataset included data pooled from 21 randomized controlled clinical trials
of secukinumab 300 or 150 or 75mg in PsO (14 Phase 3 trials and 1 Phase 4 trial), PsA (3 Phase 3 trials), and AS (3
Phase 3 trials), along with post-marketing safety surveillance data with a cut-off date of June 25, 2017. Adverse
events (AEs) were reported as exposure-adjusted incident rates (EAIRs) per 100 patient-years. Analyses
included all patients who received ≥ 1 dose of secukinumab.
Results: A total of 5181, 1380, and 794 patients from PsO, PsA, and AS clinical trials representing secukinumab exposures
of 10,416.9, 3866.9, and 1943.1 patient-years, respectively, and post-marketing data from patients with a cumulative
exposure to secukinumab of ~ 96,054 patient-years were included in the analysis. The most frequent AE was upper
respiratory tract infection. EAIRs across PsO, PsA, and AS indications were generally low for serious infections (1.4, 1.9, and
1.2, respectively), Candida infections (2.2, 1.5, and 0.7, respectively), inflammatory bowel disease (0.01, 0.05, and 0.1,
respectively), and major adverse cardiac events (0.3, 0.4, and 0.6, respectively). No cases of tuberculosis reactivation were
reported. The incidence of treatment-emergent anti-drug antibodies was low with secukinumab across all
studies, with no discernible loss of efficacy, unexpected alterations in pharmacokinetics, or association with
immunogenicity-related AEs.
Conclusions: Secukinumab demonstrated a favorable safety profile over long-term treatment in patients with
PsO, PsA, and AS. This comprehensive assessment demonstrated that the safety profile of secukinumab was
consistent with previous reports in patients with PsO, PsA, and AS, supporting its long-term use in these
chronic conditions.
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Article summary
Strengths (S) and limitations (L) of this study
 (S) Integrates safety data from a large patient
population pooled over 21 clinical trials across
multiple indications complemented with large
post-marketing surveillance safety data
 (S) Exposure-adjusted incidence rates for reporting
safety data enhances the robustness of the results by
adjusting for treatment duration
 (S) Provides valuable evidence on the comprehensive
safety profile of secukinumab that should inform
clinical decision-making
 (L) Conduct of clinical trials is protocol-specified and
may not fully reflect real-world clinical experience
and lack of a long-term placebo comparison, due to
ethical considerations, limits comparisons
 (L) Inflammatory bowel disease events were not
adjudicated and post-marketing safety surveillance
results have not been separated by individual dose
regimen or by indication
Background
Interleukin (IL)-17A is involved in mucocutaneous
defense [1] and plays a critical role in the pathogenesis of
a range of immune-mediated diseases, including psoriasis
(PsO), psoriatic arthritis (PsA), and ankylosing spondylitis
(AS) [2–4]. The disease pathogenesis of PsO, PsA, and AS
is complex and involves an interplay among environmen-
tal, genetic, and immune triggers. There is a considerable
genetic overlap with other immune-mediated diseases,
and there is often evidence of common immune dysregu-
lation, making these patients more susceptible to infec-
tions and/or adverse events (AEs) compared with the
general population [5–8]. Furthermore, introduction of a
foreign protein product, such as a monoclonal antibody,
into the human body carries the possibility of an immuno-
logic response and formation of anti-drug antibodies
(ADAs) that may impact treatment efficacy and safety [9].
The presence of co-morbidities and use of concomitant
medications further impacts these safety risks.
Biologic agents used in the management of PsO or PsA
or AS have immunomodulatory potential via their effects
on Type 17 (T helper [Th] and T Cell17) cell cytokines
and other pathways, emphasizing the need to understand
the unique safety profile of individual agents [10]. IL-17A
also plays a role in the defense against extracellular patho-
gens [10] and other immune mechanisms. Therapy for
these chronic diseases is typically intended for long-term
use and, hence, understanding the long-term efficacy and
safety of therapeutic compounds is particularly relevant
for clinical decision-making.
Fully human monoclonal antibodies are derived from
human gene sequences alone and are generally considered
to have the least immunogenic potential among biologic
agents [11]. Secukinumab, a fully human immunoglobulin
G1-kappa monoclonal antibody that directly inhibits
IL-17A, has been shown to have robust efficacy in the
treatment of moderate-to-severe PsO [12–15], PsA [16–
18], and AS [19, 20] demonstrating a rapid onset of action
and sustained long-term clinical responses with a consist-
ently favorable safety profile observed in the context of
multiple Phase 2 and 3 trials [17, 20, 21]. Secukinumab is
currently approved in > 80 countries for use in PsO/PsA/
AS with over 150,000 patients treated [22].
Here, we present integrated pooled clinical trial safety
data for secukinumab following long-term exposure of up
to 5 years in PsO and PsA and up to 4 years in AS.
Year-by-year AE rates in this cohort and the
post-marketing data available from the secukinumab peri-
odic safety update report (PSUR) submitted to global
health authorities with a reporting cut-off date of June 25,
2017, are also reported and reviewed.
Methods
Studies and patients
The integrated clinical trial safety dataset included data
pooled from 21 randomized controlled clinical trials of
secukinumab in PsO (14 Phase 3 trials and 1 Phase 4 trial;
N = 5181), PsA (3 Phase 3 trials; N = 1380), and AS (3
Phase 3 trials; N = 794) indications (see Fig. 1 for details),
along with post-marketing surveillance data for secukinu-
mab across the PsO, PsA, and AS indications from De-
cember 26, 2014 to June 25, 2017. Multiple secukinumab
dose regimens were used in these studies and included
intravenous (up to 10mg/kg) or subcutaneous (s.c.; 75,
150, or 300mg) loading followed by s.c. maintenance dos-
ing (75, 150, or 300mg). Placebo-treated patients were
re-randomized to secukinumab between 12 and 24weeks’
post-baseline in the various studies. Eligible patients aged
≥ 18 years with moderate-to-severe plaque PsO or active
PsA or AS were enrolled based on pre-specified eligibility
criteria, which, along with the design of each study, have
been reported in detail elsewhere [12, 15, 16, 18, 20, 23–
26]. Of note, patients enrolled in these trials could have
active/ongoing cardiovascular disease (unless severe or
uncontrolled), previous history of inflammatory bowel dis-
ease (IBD), including Crohn’s disease (CD) or uveitis (but
not if active and ongoing), history of basal cell carcinoma
or actinic keratosis (successfully treated with no evidence
of recurrence in the past 3months), carcinoma in situ of
the cervix or non-invasive malignant colon polyps (suc-
cessfully removed), or latent tuberculosis (TB; prophylac-
tic treatment started prior to enrollment). Patients could
continue the following medications at stable doses: sulfa-
salazine, methotrexate, corticosteroids, and non-steroidal
anti-inflammatory drugs. Patients with an inadequate re-
sponse (if taken ≥ 3months) or intolerance to tumor
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necrosis factor (TNF) inhibitors (not more than one in AS
studies and not more than 3 in PsO and PsA studies)
could also be included. Two studies (ERASURE and FIX-
TURE) in the PsO pool also allowed patients with a prior
history of usage of biologics other than TNF inhibitors
(alefacept, briakinumab, efalizumab, and ustekinumab)
after an appropriate washout period.
Safety assessments
Safety analyses included all patients who had received ≥
1 dose of study medication, with data pooled at the indi-
vidual patient level for all secukinumab treatment
groups (any secukinumab) separately for the studies by
indication. Analysis of the entire secukinumab treatment
period was performed on safety data pooled at the pa-
tient level from the date of treatment initiation up to
June 25, 2017. Analysis of the safety data was also per-
formed by the approved secukinumab 300 and 150 mg
doses separately for the studies by indication. Risks for
AEs, serious AEs (SAEs), and selected AEs were
expressed as exposure-adjusted incidence rates (EAIRs)
per 100 patient-years for the entire treatment period.
The EAIR was defined as the number of subjects ex-
posed to the drug and experiencing a certain event di-
vided by the total exposure time of all subjects who were
at risk for the event.
AEs were coded using the Medical Dictionary for
Regulatory Activities (MedDRA) version 20.0 preferred
terms (PTs) (https://www.meddra.org/). ADAs were
measured using a Meso-scale Discovery bridging assay
[27]. ADA-positive samples were analyzed to week 52
for drug-neutralizing potential, immunogenicity-related
AEs, and impact on pharmacokinetics (PK) and efficacy
of secukinumab. All clinical studies were conducted in
compliance with the Declaration of Helsinki [28], Inter-
national Council for Harmonization Guidelines for Good
Clinical Practice, and local country regulations.
Results
The results are presented here in two sections: pooled clin-
ical trial safety results and results from the post-marketing
safety surveillance. Unless specified otherwise, the results
predominantly reflect the pooled clinical trial data.
Pooled clinical trial safety results
Baseline characteristics
Pooled safety analyses included 7355 secukinumab-
treated patients with an overall exposure of 16,226.9
patient-years. A total of 5181 patients (representing
10,416.9 patient-years of exposure) were included in the
PsO pooled analyses, 1380 patients (representing 3866.9
patient-years of exposure) in the PsA pooled analyses,
and 794 patients (representing 1943.1 patient-years of
exposure) in the AS pooled analyses. Demographics and
baseline disease characteristics of the pooled secukinu-
mab groups are provided in Table 1. The baseline rates
of hypertension (39.9%), hyperlipidemia (23.0%), and
diabetes (12.4%) were comparatively higher in the PsA
pool than in the other two indications. The mean body
mass index was higher in the PsO (29.1) and PsA (29.8)
pools compared with the AS pool (27.2). The baseline
rate of uveitis was higher in the AS pool (17%), which
was expected given the propensity of this patient
population to uveitis. A history of IBD (unspecified
IBD, CD, and/or ulcerative colitis [UC]) was reported
in 15 (0.3%) PsO, 8 (0.6%) PsA, and 25 (3.1%) AS pa-
tients, respectively.
Safety summary
The EAIRs of any AE with secukinumab treatment across
the entire safety period were 204.4, 147.0, and 140.1 per
100 patient-years in the PsO, PsA, and AS pools, respect-
ively. The EAIRs of any SAE with secukinumab treatment
across the entire safety period were 6.9, 7.9, and 6.3 per
100 patient-years in the PsO, PsA, and AS pools, respect-
ively, showing no discernible pattern across the treatment
Fig. 1 Studies included in the pooled analysis. ETN etanercept, PBO placebo, UST ustekinumab
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groups. A total of 9 (0.2%) deaths were reported in the
secukinumab-treated PsO cohort (the primary reasons for
death being pulmonary embolism, arrhythmia, alcohol
poisoning, ruptured aneurysm, and myocardial infarction
[2 patients] in the secukinumab 300mg group and cere-
bral hemorrhage, cardiorespiratory arrest, and completed
suicide in the secukinumab 150mg group). There were 11
(0.8%) deaths in the PsA pool (150mg group: acute myo-
cardial infarction, septic shock, sepsis, pneumonia, meta-
static small cell lung cancer, pancreatic carcinoma, and
cardiac failure [2 patients]; 75mg group: squamous cell
carcinoma of the pharynx, myocardial infarction, and
cerebrovascular event) and 5 (0.6%) in the AS pool (150
mg group: 1 unknown; 75mg group: acute respiratory fail-
ure, cerebrovascular accident, acute myocardial infarction,
and respiratory arrest). Discontinuations due to AEs num-
bered 331 (6.4%), 104 (7.5%), and 58 (7.3%) in the PsO,
PsA, and AS pools, respectively (Table 2). The EAIRs of
selected AEs with secukinumab were comparable across
the PsO, PsA, and AS studies (Table 3). The rates were
comparable with those reported previously [15, 16, 18,
20], and no new safety signals were identified from those
reported previously.
Infections
Over the entire safety period, upper respiratory tract infec-
tion (URTI) was the most common type of infection across
all indications. In an overall dataset of 7355 patients, the
EAIRs for serious infections were 1.4, 1.9, and 1.2 per 100
patient-years in the PsO, PsA, and AS pools, respectively
(Table 3). A total of 14 cases (EAIR of 0.13 per 100
patient-years) of opportunistic infections were reported in
the PsO pool, which included 10 cases of esophageal can-
didiasis, 3 cases of gastrointestinal candidiasis, and 1 case
of herpes zoster infection. Eight cases (EAIR of 0.21 per
100 patient-years) of opportunistic infections were reported
in the PsA pool, which included 4 cases of esophageal can-
didiasis and 1 case each of herpes zoster infection, toxo-
plasmosis, Mycobacterium avium complex infection, and
pneumonia. The 2 cases (EAIR of 0.1 per 100 patient-years)
of opportunistic infections reported in the AS pool were
herpes zoster infection and esophageal candidiasis. A total
of 5 cases (EAIR of 0.05 per 100 patient-years) of sepsis
(PT) were reported in the PsO pool, 3 (EAIR of 0.08 per
100 patient-years) in the PsA pool, and none in the AS
pool. Most infections were mild to moderate.
Candida infection
Cutaneous or mucosal Candida infection (MedDRA
high-level term) was reported in 221 (EAIR of 2.2 per
100 patient-years) patients across the PsO studies, 57
(EAIR of 1.5 per 100 patient-years) patients across the
PsA studies, and 13 (EAIR of 0.7 per 100 patient-years)
patients across the AS studies (Table 3 and Add-
itional file 1: Table S1). All cases of Candida infection
were localized, most were mild or moderate in severity
(except for 4 cases in the PsO pool that were considered
severe), were self-limited or responsive to standard treat-
ment, and did not lead to discontinuation of study treat-
ment. No cases of systemic candidiasis were reported in
patients treated with secukinumab across all studies.
Table 1 Baseline demographics and disease characteristics of pooled clinical trial patient population
Characteristic PsO studies PsA studies AS studies
Any secukinumab
N = 5181
Any secukinumab
N = 1380
Any secukinumab
N = 794
Age (years), mean (SD) 45.7 (13.3) 48.8 (12.0) 42.4 (12.3)
Female, n (%) 1743 (33.6) 742 (53.8) 265 (33.4)
Caucasian, n (%) 4236 (81.8) 1212 (87.8) 612 (77.1)
BMI, mean (SD) 29.1 (6.6) 29.8 (6.3) 27.2 (5.5)
Relevant medical history or current medical condition, n (%)
Hypertension 1089 (21.0) 551 (39.9) 176 (22.2)
Hyperlipidemia 667 (12.9) 318 (23.0) 65 (8.2)
Diabetes mellitus 341 (6.6) 171 (12.4) 22 (2.8)
IBD 0 (0) 4 (0.3) 17 (2.1)
Crohn’s disease 5 (0.1) 2 (0.1) 5 (0.6)
Ulcerative colitis 10 (0.2) 2 (0.1) 3 (0.4)
Uveitis 0 (0) 8 (0.6) 135 (17.0)
Current smoker 1585 (30.6) 262 (19.0) 234 (29.5)
Anti-TNF inadequate responder 784 (15.1) 435 (31.5) 227 (28.6)
AS ankylosing spondylitis, BMI body mass index, IBD inflammatory bowel disease, N number of patients in the analysis, n number of patients with a response, PsA
psoriatic arthritis, PsO psoriasis, SD standard deviation, TNF tumor necrosis factor
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Neutropenia
Over the entire treatment period, the EAIRs per 100
patient-years for neutropenia with secukinumab treatment
were 0.3, 0.2, and 0.5 in the PsO, PsA, and AS studies, re-
spectively (Table 3). In the PsO pool, grade 3 neutropenia
(defined as an absolute neutrophil count between 1.0 and
0.5 × 109/L) was reported in 33 (0.6%) patients and grade 4
neutropenia (defined as an absolute neutrophil count of less
than 0.5 × 109/L) was reported in 2 (0.04%) patients. Of the
cases of neutropenia, 7 were reported as severe, while the
remaining were mild or moderate in severity (viral URTI
was the most frequently co-reported AE [17 cases]); there
Table 3 Selected AEs with secukinumab across pooled clinical trials
Variable PsO studies PsA studies AS studies
Any secukinumab
N = 5181
Any secukinumab
N = 1380
Any secukinumab
N = 794
EAIR per 100 patient-years (95% CI)
Serious infections1 1.4 (1.2, 1.6) 1.9 (1.5, 2.4) 1.2 (0.8, 1.8)
Candida infections2 2.2 (1.9, 2.5) 1.5 (1.1, 2.0) 0.7 (0.4, 1.2)
IBD3 0.01 (0.00, 0.05) 0.05 (0.01, 0.2) 0.1 (0.0, 0.3)
Crohn’s disease3 0.05 (0.02, 0.1) 0.08 (0.02, 0.2) 0.4 (0.2, 0.8)
Ulcerative colitis3 0.1 (0.07, 0.2) 0.08 (0.02, 0.2) 0.2 (0.1, 0.5)
MACE4 0.3 (0.2, 0.5) 0.4 (0.3, 0.7) 0.6 (0.3, 1.1)
Neutropenia3 0.3 (0.2, 0.4) 0.2 (0.1, 0.4) 0.5 (0.3, 1.0)
Uveitis3 0.02 (0.0, 0.07) 0.1 (0.0, 0.2) 1.4 (0.9, 2.0)
Malignancy5 0.8 (0.6, 1.0) 1.1 (0.8, 1.5) 0.5 (0.2, 0.9)
Approximation was not done if EAIR is less than 0.1
1Values are based on system organ class: infections and infestations
2Values are based on the high-level term
3Values are based on the preferred term
4Values are based on Novartis MedDRA query, which comprises (1) any MI, (2) any CVA, and (3) all other CV events that are fatal, out of a listing of 2200+ terms
5Values are based on standardized MedDRA query
AE adverse event, AS ankylosing spondylitis, CI confidence interval, CV cardiovascular, CVA CV accident, EAIR exposure-adjusted incidence rate per 100 patient-
years, IBD inflammatory bowel disease, MACE major adverse cardiovascular event, MedDRA Medical Dictionary for Regulatory Activities, MI myocardial infarction, N
number of patients in the analysis, n number of patients with a response, PsA psoriatic arthritis, PsO psoriasis
Table 2 Summary of pooled safety data from secukinumab clinical trials
PsO studies PsA studies AS studies
Any secukinumab
N = 5181
Any secukinumab
N = 1380
Any secukinumab
N = 794
Total exposure, pt-years 10,416.9 3866.9 1943.1
Min–max exposure (days) 1–1825 8–1827 1–1530
Death, n (%) 9 (0.2) 11 (0.8) 5 (0.6)
Discontinuations due to AEs, n (%) 331 (6.4) 104 (7.5) 58 (7.3)
AEs, EAIR per 100 pt-years (95% CI)
Any AE 204.4 (198.4, 210.5) 147.0 (138.9, 155.5) 140.1 (129.8, 151.0)
Any serious AE 6.9 (6.3, 7.4) 7.9 (7.0, 8.9) 6.3 (5.2, 7.6)
Most common AEs1
Viral URTI2 21.0 (19.9, 22.0) 12.1 (10.9, 13.4) 9.8 (8.4, 11.5)
Headache 6.2 (5.8, 6.8) 3.8 (3.2, 4.5) 5.3 (4.3, 6.5)
Diarrhea 3.8 (3.4, 4.2) 3.7 (3.1, 4.4) 5.2 (4.2, 6.4)
URTI 5.4 (4.9, 5.9) 9.1 (8.1, 10.2) 5.2 (4.2, 6.4)
1AEs in the secukinumab group that occurred with an IR > 5.0 during the entire safety period in any of the pooled groups
2Includes cases of common cold (LLT)
AE adverse event, AS ankylosing spondylitis, CI confidence interval, EAIR exposure-adjusted incidence rate per 100 patient-years, IR incidence rate, LLT low-level
term, N number of patients in the analysis, n number of patients with a response, PsA psoriatic arthritis, PsO psoriasis, pt patient, URTI upper respiratory
tract infection
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were 5 cases in which study treatment was withdrawn. In
the PsA pool, 12 (0.9%) patients reported grade 3, and 3
(0.2%) patients reported grade 4 neutropenia. All cases
were either mild or moderate in severity (anemia, diar-
rhea, fatigue, leukopenia, URTI, and urinary tract infection
were the most frequently co-reported AEs [3 cases each]),
with 1 instance in which study treatment was withdrawn.
In the AS pool, 9 (1.1%) patients reported grade 3, and 5
(0.6%) patients reported grade 4 neutropenia in the AS
pool. All cases of neutropenia reported in the AS pool
were either mild or moderate in severity (diarrhea was the
most frequently co-reported AE [4 cases]), with none lead-
ing to study treatment discontinuation.
Inflammatory bowel disease
The EAIRs per 100 patient-year exposure for CD, UC,
or unspecified IBD combined ranged from 0.01 to 0.1 in
PsO, 0.05 to 0.08 in PsA, and 0.1 to 0.4 in the AS pools
(Table 3). There were 41 (0.6%) reported cases of IBD
(including CD and UC). Of these, 30 (0.4%) were
new-onset cases. Across indications, 14 (0.2%) patients
who reported IBD discontinued the study.
Major adverse cardiovascular events
The EAIR per 100 patient-years for major adverse car-
diovascular events (MACE) with secukinumab treatment
over the entire treatment period was 0.3, 0.4, and 0.6 in
the PsO, PsA, and AS pools, respectively (Table 3).
Uveitis
In the PsO pool, the EAIR for uveitis was 0.02 per 100
patient-years over the entire treatment period; all cases of
uveitis (n = 2) were de novo. In the PsA pool, the EAIR for
uveitis was 0.1 per 100 patient-years over the entire treat-
ment period; all cases of uveitis (n = 3) were de novo. The
EAIR for uveitis in the AS pool was 1.4 per 100
patient-years over the entire treatment period; a total of
12 (46%) cases were de novo (Table 3). Among all cases of
uveitis (n = 26) in the AS pool, one was reported as severe
and the remainder were reported as mild or moderate. A
total of 135 (17%) patients in the AS pool reported
pre-existing (but not active or ongoing) uveitis at baseline,
and 589 (74.2%) were HLA-B27 positive, which has a
known association with the development of uveitis.
Malignancy
Malignant or unspecified tumors (Standardized MedDRA
Queries [SMQ]) were reported in 81 patients (EAIR of 0.8
per 100 patient-years) in the PsO pool, which included 76
patients with non-hematological malignant tumors, 2 pa-
tients each with a hematological malignant tumor or a
non-hematological tumor of unspecified malignancy, and 1
patient with a hematological tumor of unspecified ma-
lignancy. In the PsA pool, malignant or unspecified
tumors were reported in 43 patients (EAIR of 1.1 per
100 patient-years), which included 37 patients with
non-hematological malignant tumors, 5 patients with a
non-hematological tumor of unspecified malignancy,
and 1 patient with a hematological malignant tumor. In
the AS pool, malignant or unspecified tumors were re-
ported in 9 patients (EAIR of 0.5 per 100 patient-years),
which included 6 patients with non-hematological ma-
lignant tumors, 2 patients with a non-hematological
tumor of unspecified malignancy, and 1 patient with a
hematological malignant tumor.
Suicidality
Over the entire treatment period, in the PsO studies, 8
patients (0.2%) reported some form of suicidality-related
AEs, including 4 attempted suicides, 1 completed sui-
cide, 2 cases of suicidal ideation, and 1 case of suicidal
depression. Three cases (0.2%) of suicidal ideation were
reported in the PsA studies. All suicidality cases pre-
sented at least one of the following: depression, anxiety,
insomnia, bipolar disorder, co-medication with psycho-
active drugs, alcoholism, and/or ongoing psychological
or socio-economic issues. No cases of suicidality-related
AEs were reported in the AS studies on secukinumab
treatment. These suicidality safety results with secukinu-
mab were consistent with an earlier report from a
pooled analysis of data from 10 clinical studies in
moderate-to-severe plaque PsO [29].
Immunogenicity
Treatment-emergent ADAs were reported with secuki-
numab in < 1% of patients across all studies at week 52.
All treatment-emergent ADAs were associated with nor-
mal PK [30], and none were associated with loss of secu-
kinumab efficacy or immunogenicity-related AEs.
Injection site reactions
The EAIR of injection site reactions (high-level term) was
1.2, 1.3, and 0.8 in the PsO, PsA, and AS pools, respectively.
Incidence of AEs by secukinumab dose
Safety data for any AE, any SAE, serious infections, Can-
dida infection, IBD, and MACE for the approved 300
and 150 mg secukinumab dose are shown in Add-
itional file 1: Table S2. The EAIRs were generally com-
parable, and there was no dose-response relationship
observed in terms of safety events with secukinumab
treatment within each indication.
Incidence of AEs year-by-year
Data on a year-by-year basis for any AE, any SAE, ser-
ious infections, Candida infection, IBD, and MACE
showed no increase with secukinumab treatment over
time across studies within each indication (Fig. 2). The
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EAIR per 100 patient-years for uveitis on a year-by-year
basis was as follows: 0.02 (N = 5181; year 1), 0.0 (N =
3268; year 2), 0.0 (N = 2246; year 3), 0.07 (N = 1627; year
4), and 0.0 (N = 1210; year 5) in PsO clinical trials; 0.2
(N = 1380; year 1), 0.0 (N = 1183; year 2), 0.0 (N = 948;
year 3), 0.2 (N = 587; year 4), and 0.0 (N = 290; year 5) in
PsA clinical trials; and 1.1 (N = 794; year 1), 1.9 (N = 700;
year 2), 2.2 (N = 557; year 3), and 2.5 (N = 332; year 4) in
AS clinical trials.
Post-marketing safety surveillance results
The cumulative post-marketing exposure to secukinumab
was estimated to be ~ 96,054 patient-years across the ap-
proved indications (Table 4). The exposure-adjusted
reporting rates (EARRs) for infections and serious infec-
tions were 4.7 and 1.8 per 100 patient-years, respectively.
Neutropenia was reported at a rate of 0.07 per 100
patient-years. The reporting rate of hypersensitivity was
2.4 per 100 patient-years. The EARRs for malignancies
and MACE were both 0.2 per 100 patient-years, with most
assessable cases having multiple confounders, risk factors,
or alternative explanations for the events. IBD was re-
ported at a rate of 0.2 per 100 patient-years. The reporting
rate for suicidal ideation and behavior was 0.04 per 100
patient-years. Twenty-nine cases of opportunistic
infections were reported in the post-marketing data, in-
cluding 5 cases of TB infection (no reactivation cases), 2
cases of herpes infection, and 17 cases of esophageal can-
didiasis. There was 1 case of immunogenicity, and no
cases of either hepatitis B reactivation or interactions with
live vaccines were reported. The safety profile from the
PSUR was consistent to that reported in randomized clin-
ical trials (RCTs) with secukinumab.
Discussion
In this large safety analysis (n = 7355; mean exposure
= 16,226.9 patient-years) of 21 clinical trials spanning
up to 5 years of treatment for PsO and PsA and up
to 4 years of treatment for AS and with safety data
from post-marketing surveillance database spanning
~ 96,054 patient-years, secukinumab was associated
with a generally low frequency of AEs, with no dis-
cernible pattern regarding SAEs across the treatment
groups in all indications. The most frequently re-
ported AE was URTI. EAIRs of selected AEs, namely
serious infections, Candida infections, IBD, and
MACE, were consistent with previous reports, with
no new safety signals across any indication.
Secukinumab selectively targets IL-17A, a downstream
product of Type 17 cells, and leaves the other functions
Fig. 2 EAIR of AEs year-by-year with secukinumab. Patients included in the analysis: PsO: year 1 (N = 5181), year 2 (N = 3268), year 3 (N = 2246),
year 4 (N = 1627), and year 5 (N = 1210); PsA: year 1 (N = 1380), year 2 (N = 1183), year 3 (N = 948), year 4 (N = 587), and year 5 (N = 290); AS: year 1
(N = 794), year 2 (N = 700), year 3 (N = 557), and up to year 4 (N = 332). *Data shown for patients (N = 332) with data beyond the week 156 calendar
date (up to 4 years). aRates are for the system organ class which includes multiple associated PTs. bRates are for Candida infections high-level term
which includes multiple associated PTs. cRates are for PT (IBD PT data are reported for unspecified IBD). dRates are for the Novartis MedDRA Query
term which comprises [1] any MI, any CVA, and [2] all other CV events that are fatal, out of a listing of 2200+ terms. AE adverse event, AS ankylosing
spondylitis, CV cardiovascular, CVA CV accident, EAIR exposure-adjusted incidence rate per 100 patient-years, IBD inflammatory bowel disease, MedDRA
Medical Dictionary for Regulatory Activities, MACE major adverse cardiovascular event, MI myocardial infarction, N number of patients in the analysis,
PsO psoriasis, PsA psoriatic arthritis, PT preferred term, SAE serious AE
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of Th17 cells intact (e.g., the release of IL-22 and TNF)
thus limiting the scope for off-target-related effects with
secukinumab compared with other biologics. It does not
directly influence the Th1 pathway and, thus, is expected
to leave Th1-based host immunity largely intact, which
may improve the overall safety profile [3, 4, 10]. An in-
creased risk of infections is potentially associated with
any immunomodulatory biologic agent [31]. Further-
more, the immune dysregulations underlying severe PsO
and spondyloarthritis are also recognized risk factors for
an increased potential of developing infections [32]. The
use of systemic therapies for PsO seems to further in-
crease this risk of infections [33]. In this analysis, serious
infections ranged between an EAIR of 1.2 and 1.9 per
100 patient-years in clinical trials with no clinically
meaningful differences in EAIRs across the indications.
This incidence of treatment-emergent infections is
particularly reassuring and is an important clinical con-
sideration in the management of patients with
immune-mediated diseases such as PsO, PsA, and AS.
Neutrophils are important mediators and regulators of
innate and adaptive immune responses, and a reduction
in peripheral neutrophil counts is a potential effect of
immune-modulating agents [34–36], including tofaciti-
nib, brodalumab, and ixekizumab [37, 38]. Over the en-
tire treatment period in this clinical trial safety pool, the
EAIRs per 100 patient-years for neutropenia with secuki-
numab were 0.3, 0.2, and 0.5 in the PsO, PsA, and AS
studies, respectively. Also, in the post-marketing safety
surveillance, neutropenia was reported as uncommon
(EARR of ≥ 1/1000 to < 1/100).
In this large clinical trial safety analysis, the EAIR
per 100 patient-years exposures for CD or UC or
unspecified IBD was low and ranged between 0.01
and 0.1 in the three cohorts. Discontinuations due
to IBD were low with secukinumab (14 [0.19%]).
Also, in the post-marketing safety surveillance ana-
lysis, the cumulative reporting rate of IBD remained
stable at approximately 0.2 reported events per 100
patient-years. Incidence rates per 100 patient-years
of CD and UC have been reported in the literature
ranging from ~ 0.3 in PsO, 0.1 in PsA, and 0.7 in
AS patients [39–41]. Previous exposure to anti-TNF
agents and smoking are identified risk factors for
Table 4 Summary of secukinumab post-marketing safety: cumulative and across five PSUR periods
Reporting period 26 Dec 2014–25
June 2015
26 June 2015–25
Dec 2015
26 Dec 2015–25
June 2016
26 June 2016–25
Dec 2016
26 Dec 2016–25
June 2017
Cumulative
rate
Exposure 1838 7450 16,871 28,549 41,346 96,054
Infections and infestations/serious infections and infestations
Cases (n) 178/89 495/149 712/232 1136/475 1730/573 4483/1688
EARR (per 100 PY) 9.7/4.8 6.6/2.0 4.2/1.4 4.0/1.7 4.2/1.4 4.7/1.8
Neutropenia
Cases (n) 0 11 12 22 24 66
EARR (per 100 PY) 0 0.2 0.07 0.08 0.06 0.07
Hypersensitivity
Cases (n) 82 293 425 573 752 2293
EARR (per 100 PY) 4.5 3.9 2.5 2.0 1.8 2.4
Malignant or unspecified tumors
Cases (n) 2 15 21 50 76 173
EARR (per 100 PY) 0.1 0.2 0.1 0.2 0.2 0.2
Total IBD
Cases (n) 4 12 37 46 93 195
EARR (per 100 PY) 0.2 0.2 0.2 0.2 0.2 0.2
MACE
Cases (n) 6 15 16 39 58 148
EARR (per 100 PY) 0.3 0.2 0.09 0.1 0.1 0.2
SIB
Cases (n) 1 3 6 8 12 35
EARR (per 100 PY) 0.05 0.04 0.04 0.03 0.03 0.04
Approximation was not done if EARR is less than 0.1
EARR exposure-adjusted reporting rates, IBD inflammatory bowel disease, MACE major adverse cardiovascular events, PSUR periodic safety update report, PY
patient-treatment years, SIB suicidal ideation and behavior
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IBD exacerbation [42, 43]. In this safety pool, almost
one third of all PsA and AS patients were previously
exposed to anti-TNF treatments (with an inadequate
response or intolerance); previous biologic exposure
was also apparent in the PsO cohort, but the rates
were lower (15.1%). Each cohort also included a
sizeable patient population of current smokers at
baseline (~ 30% in PsO and AS, and 19% in PsA).
Nevertheless, the overall observed incidence of IBD,
including new-onset cases, and discontinuations of
secukinumab treatment due to IBD, was uncommon
(< 1%). It is important to emphasize that while pa-
tients with a previous history of IBD, including CD
or UC, could enroll in these trials, the risk of IBD
in this cohort could be different from that observed
in the real-world, as patients with active IBD were
excluded from all clinical trials [40, 44].
Incidences of suicidality-related AEs were low in the
PsO and PsA studies, and none were reported in the AS
studies. There was no evidence to suggest that treatment
with secukinumab increases the risk of suicidality-related
AEs beyond background risk in patients with these sys-
temic inflammatory diseases [45, 46].
The incidence of treatment-emergent ADAs was low
with secukinumab across all studies evaluated, with no
discernible loss of efficacy, unexpected alterations in PK,
or association with immunogenicity-related AEs. Con-
sidering the reported potential for immunogenicity with
secukinumab as compared with other biologic agents
[47, 48], this is particularly reassuring and relevant for
clinical decision-making.
AE rates calculated on a year-by-year interval basis
did not show an increased rate over time for most
selected AEs with secukinumab treatment and re-
vealed no new safety signals. EAIR for uveitis was
generally low across the three indications. In the AS
clinical trials, considering the background rate of
uveitis medical history of 17% in the patient popula-
tion, the decreasing sample size for each subsequent
yearly interval may be skewing the EAIRs, given the
relative low absolute number of uveitis events re-
ported each year (skewing would be less evident for
higher EAIRs). The year-by-year rates should be
followed closely as additional long-term exposure
data are accumulated. The observed rates of flares
and even new-onset uveitis with secukinumab was
low and reassuring given the background rate of
uveitis in the medical history of this pool (especially
in AS patients).
Post-marketing safety data are considered complemen-
tary to data from RCTs. Secukinumab was associated
with a consistent safety profile in the post-marketing set-
ting across five successive PSUR periods (Dec 26, 2014,
to June 25, 2017), with a cumulative post-marketing
exposure estimated to be ~ 96,054 patient-years in the
approved indications of PsO, PsA, and AS.
Additionally, a recent analysis assessed the outcomes
of pregnancies from this safety cohort, which did not
find any evidence for increased rates of adverse preg-
nancy outcomes with secukinumab. However, the ana-
lysis was limited by a sizeable amount of missing
outcome data and relatively short exposure to secukinu-
mab [49, 50].
Despite reassuring findings, there are limitations to
this safety analysis. The conduct of clinical trials is
protocol-specified, which may not fully reflect real-world
clinical experience. Some studies included in the analysis
differ in terms of baseline selection criteria, patient char-
acteristics, and treatment regimens, which is a methodo-
logical limitation. However, pooling of data from large
clinical trials and post-authorization safety surveillance
has enabled a more comprehensive overview of the
safety profile of secukinumab. It should be noted that
IBD events were not adjudicated in this analysis. The
lack of a long-term placebo comparison, due to ethical
considerations, limits comparisons. Furthermore, the
post-marketing safety surveillance results have not been
separated by individual dose regimen or by indication.
Rather than using only crude incidence rates, this report
included the more robust safety assessment rate by using
EAIRs which adjust for potential differences in duration
of drug exposure. We believe that factors such as under-
lying disease activity, co-morbid conditions, and con-
comitant medications in the patient population are
unlikely to have confounded these reported events, but
this was not assessed, as it was beyond the scope of the
current analyses. The strength of this report is the fact
that this integrates safety data from a large patient popu-
lation pooled over 21 clinical trials across multiple indi-
cations, and is complemented with large post-marketing
surveillance safety data. The use of EAIRs also enhances
the robustness of the results by adjusting for treatment
duration. Thus, this report provides valuable evidence
on the comprehensive safety profile of secukinumab that
should inform clinical decision-making.
Summary
Secukinumab demonstrated a favorable safety profile
over long-term treatment in patients with PsO, PsA,
and AS. The safety profile of secukinumab was con-
sistent in these pooled patient populations and with
what has been reported earlier for individual studies
of secukinumab [12, 13, 15–21, 23, 24, 26, 49]. This
long-term (up to 5 years) safety assessment provides a
broader understanding of the safety of secukinumab
and supports its long-term use in these chronic sys-
temic inflammatory conditions.
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